6-(4-morpholinylcarbonyl)nicotinic acid tert-butyl ester | 163587-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 6-(4-morpholinylcarbonyl)nicotinic acid tert-butyl ester
• 英文别名: 6-(Morpholine-4-carbonyl)nicotinic acid, t-butyl ester；tert-butyl 6-(morpholine-4-carbonyl)pyridine-3-carboxylate
• CAS: 163587-56-2
• 化学式: C₁₅H₂₀N₂O₄
• 分子量: 292.335
• InChiKey: QCLVLJHVKGUQFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(4-morpholinylcarbonyl)nicotinic acid tert-butyl ester 在 盐酸 作用下， 以 硝基甲烷 为溶剂， 反应 0.33h， 以68%的产率得到6-[(morpholin-4-yl)carbonyl]pyridine-3-carboxylic acid
  参考文献：
  名称：

  Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones. 2. Orally Active PG-Val-Pro-Val Pentafluoroethyl Ketones

  摘要：

  Valylprolylvalyl pentafluoroethyl ketones with different N-protecting groups were evaluated in vitro and in vivo as inhibitors of human neutrophil elastase (HNE). Several of these compounds were found to be orally active in HNE-induced rat and hamster lung hemorrhage models. The compound with 4-(4-morpholinylcarbonyl)benzoyl as the protecting group, 71 (MDL 101,146), was studied in greater detail. Hydration and epimerization studies were performed on 71 and related compounds in various media, including human blood serum. Highperformance liquid chromatography studies on a reversed-phase system as a measure of the Lipophilicity of 71. and related compounds revealed a small range of relative retention times wherein the orally active compounds fell. The K-i value determined for 71 vs HNE was 25 nM.

  DOI：

  10.1021/jm00052a013
• 作为产物：
  描述：

  吗啉 、 5-tert-butyl 2-methyl pyridine-2,5-dicarboxylate 以 四氢呋喃 为溶剂， 反应 72.0h， 以47%的产率得到6-(4-morpholinylcarbonyl)nicotinic acid tert-butyl ester
  参考文献：
  名称：

  Inhibition of Human Neutrophil Elastase with Peptidyl Electrophilic Ketones. 2. Orally Active PG-Val-Pro-Val Pentafluoroethyl Ketones

  摘要：

  Valylprolylvalyl pentafluoroethyl ketones with different N-protecting groups were evaluated in vitro and in vivo as inhibitors of human neutrophil elastase (HNE). Several of these compounds were found to be orally active in HNE-induced rat and hamster lung hemorrhage models. The compound with 4-(4-morpholinylcarbonyl)benzoyl as the protecting group, 71 (MDL 101,146), was studied in greater detail. Hydration and epimerization studies were performed on 71 and related compounds in various media, including human blood serum. Highperformance liquid chromatography studies on a reversed-phase system as a measure of the Lipophilicity of 71. and related compounds revealed a small range of relative retention times wherein the orally active compounds fell. The K-i value determined for 71 vs HNE was 25 nM.

  DOI：

  10.1021/jm00052a013

文献信息

• Novel elastase inhibitors
  申请人：——

  公开号：US20030096759A1

  公开（公告）日：2003-05-22

  This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P 2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.

  本发明涉及一种抑制弹性蛋白酶的化合物，特别是人类中性粒细胞弹性蛋白酶。这些抑制剂是短的合成肽，在其中P2基团被各种含氮杂环基团所替代。作为人类中性粒细胞弹性蛋白酶的抑制剂，这些化合物在治疗患有中性粒细胞相关炎症性疾病的患者中是有用的。
• Substituted oxazolidine calpain and/or cathepsin B inhibitors
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05691368A1

  公开（公告）日：1997-11-25

  This invention relates to oxazolidine inhibitors of calpain and/or cathepsin B and to compositions containing them. As inhibitors of calpain and/or cathepsin B, the compounds are useful in the treatment of patients afflicted with acute or chronic neurodegenerative disorders.

  本发明涉及氧杂环丙氨酸对卡钙蛋白酶和/或B型蛋白酶的抑制剂及其组合物。作为卡钙蛋白酶和/或B型蛋白酶的抑制剂，这些化合物可用于治疗患有急性或慢性神经退行性疾病的患者。
• Acylated enol derivatives as prodrugs of elastase inhibitors
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05698523A1

  公开（公告）日：1997-12-16

  This invention relates to acylated enol derivatives of known elastase inhibitors. These compounds are useful in the treatment of various inflammatory diseases, including cystic fibrosis and emphysema or as prodrugs of compounds which are useful in the treatment of said diseases.

  本发明涉及已知弹性酶抑制剂的酰化烯醇衍生物。这些化合物可用于治疗各种炎症性疾病，包括囊性纤维化和肺气肿，或作为有用于治疗该类疾病的化合物的前药。
• Perfluoroalkyl ketone inhibitors of elastase and processes for making
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US06008196A1

  公开（公告）日：1999-12-28

  This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase, and to novel processes for making the same. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.

  本发明涉及一种抑制弹性蛋白酶的化合物，特别是人类中性粒细胞弹性蛋白酶的抑制剂，并涉及制备该化合物的新型方法。作为人类中性粒细胞弹性蛋白酶的抑制剂，这些化合物在治疗患有中性粒细胞相关炎症疾病的患者中非常有用。
• Orally-active elastase inhibitors
  申请人：Merrell Pharmaceuticals, Inc.

  公开号：US06265381B1

  公开（公告）日：2001-07-24

  This invention relates to novel morpholinourea and related derivatives of pentafluoroethyl peptides which are orally active elastase inhibitors. These compounds are useful in the treatment of various inflammatory diseases and emphysema.

  本发明涉及新型噻唑烷脲和五氟乙基肽相关衍生物，这些衍生物是口服活性的弹性蛋白酶抑制剂。这些化合物在治疗各种炎症性疾病和肺气肿方面是有用的。